Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-230 in on-pump cardiac surgery (phase II)
2015-005600-28Phase 2Completed
- Sponsor
- Exponential Biotherapies, Inc.
- Start
- Feb 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Systemic Inflammatory Response Syndrome (SIRS) and acute kidney failure (AKF) comparing EA-230 with Placebo (2 arms). Primary endpoint: Safety and tolerability of EA-230. Started Feb 2016; status: completed.
02
Drugs
EA-230
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)acute kidney failure (AKF)
Beyond the preview
Go deeper on 2015-005600-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005600-28.